Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Harlan Labs Expands Imaging Services and Disease-Validated Models | Contract Pharma

What are you searching for?

Sign in
Breaking News

Harlan Labs Expands Imaging Services and Disease-Validated Models

Offers expanded capabilities at Israel research center

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Harlan Laboratories has expanded its disease-preconditioned animal model and imaging services at its specialty research center in Israel. Through the expansion, Harlan offers chemically, genetically and surgically preconditioned models for disease states including: autoimmune disease, diabetes, cancer, tissue repair, metabolism and obesity, and osteoporosis. In addition, Harlan has expanded its imaging services with MRI and CT scanning technology for evaluating therapeutic options in animal models. 
 
“Harlan has developed proven, GLP-validated methods for inducing specific disease-state phenotypic responses in research models, which helps our customers assess the therapeutic benefits of their pharmaceutical compounds, biological products and medical devices,” said Joe Meyer, vice president of Global Commercial Operations, Harlan Laboratories. “By supplying the experimental models, conducting the evaluation study and reporting the results, Harlan provides a comprehensive service platform for the evaluation of potential therapies and devices.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics